Tablas de Dosis Calculadora Mezclas & Stacks Aprender Blog Péptidos
Abrir Calculadora
Tablas de Dosis  ›  PNC-27
Other

PNC-27 Guía & Tabla de Dosis

A p53-derived peptide researched for selective effects on cancer cells.

Vida mediashort
Víasubcutaneous
PNC-27 — Tabla de dosis
Cada fila citada
ObjetivoDosisFrecuenciaDuraciónEvidenciaFuente
Los datos de dosis citados de este compuesto se están compilando.
Solo para uso de investigación y educativo. No es consejo médico.

What is PNC-27?

PNC-27 is a short, synthetic peptide made up of 32 amino acids. It was designed in the lab by combining two pieces: one chunk borrowed from the tumor-suppressor protein p53 (specifically the region that normally grabs onto a protein called HDM-2), and a second chunk called a cell-penetrating peptide (CPP) leader sequence that helps the whole molecule get close to a cell's outer surface.[1] The result is a chimeric — meaning "mixed origin" — molecule that researchers are studying for its ability to tell cancer cells apart from healthy ones and act on them selectively.[1] PNC-27 is strictly a research compound and is not approved for human use.

How PNC-27 Works

Think of HDM-2 as a doorbell that only gets installed on cancer cell front doors. Normal, healthy cells keep HDM-2 tucked away inside the cell. Many cancer cells, however, display HDM-2 right on the outside of their membrane — like a name tag.[1] PNC-27 is engineered to recognize that name tag.

Here is the sequence of events researchers have observed in lab studies:

  • Step 1 — Docking. PNC-27 binds to membrane-expressed HDM-2 on the cancer cell surface, forming a 1-to-1 complex.[1]
  • Step 2 — Pore formation. Multiple PNC-27/HDM-2 complexes cluster together in ring-shaped structures, punching physical holes — called transmembrane pores — through the cancer cell's outer wall.[1]
  • Step 3 — Cell lysis. With holes in its membrane, the cancer cell can't maintain its internal environment. Contents spill out and the cell dies by a process called necrosis.[1]
  • Step 4 — Mitochondrial disruption. Researchers have also observed PNC-27 entering cancer cells and binding to mitochondrial membranes, disrupting those energy-producing organelles as well — adding another layer of cell death.[2]

Normal cells, which don't display HDM-2 on their surface, are left alone. In one experiment, untransformed (non-cancerous) fibroblasts treated with PNC-27 showed no pore formation at all.[1]

What the Research Shows

Lab studies have tested PNC-27 across a range of cancer cell types, always checking whether normal cells are harmed at the same time.

Leukemia cells

In studies using three different human leukemia cell lines (U937, OCI-AML3, and HL-60), PNC-27 caused measurable cell death within just four hours. Normal hematopoietic (blood-forming) cells were not affected.[5] The researchers confirmed that all three leukemia lines expressed HDM-2 on their membranes at high levels — explaining why PNC-27 targeted them.[5]

Cervical cancer cells

A 2025 study tested PNC-27 on human cervical squamous cancer cells (HTB-35) versus normal cervical cells (PCS-480). The cancer cells were killed even at low doses (IC50 of about 12.4 µM in that model), while normal cervical cells were unharmed. The cancer cells showed clear HDM-2 expression on their membranes; the normal cells did not.[4]

Pancreatic cancer and mitochondria

Using pancreatic carcinoma cells (MIA-PaCa-2), scientists confirmed that blocking HDM-2's p53-binding site with a specific antibody also blocked PNC-27's killing effect — proving the mechanism depends on that interaction.[2] They also showed that mitochondria in treated cancer cells failed to retain a marker dye, while lysosomes (another organelle) stayed intact, suggesting PNC-27 selectively disrupts mitochondria too.[2]

Ovarian cancer combination therapy

Researchers explored whether PNC-27 could work alongside paclitaxel — a common chemotherapy drug — against ovarian cancer cells. They found evidence of synergy: the combination appeared more effective than either agent alone, potentially because paclitaxel and PNC-27 attack cells through different pathways.[6]

Nanoparticle delivery research

One laboratory study attached PNC-27 to iron oxide nanoparticles (SPIONs) to explore whether the peptide could act as a targeting molecule for cancer imaging. The conjugated nanoparticles bound to HDM-2-expressing cancer cells far more than to normal cells, suggesting PNC-27 could one day guide diagnostic tools as well as therapeutic ones.[3]

What PNC-27 Is Being Studied For

  • Selective killing of multiple solid tumor types (pancreatic, cervical, ovarian cancers)[1][4][6]
  • Blood cancers including acute myelogenous leukemia subtypes[5]
  • Combination strategies with existing chemotherapy drugs[6]
  • Cancer imaging and early detection via nanoparticle conjugation[3]
  • Understanding the basic biology of membrane-bound HDM-2 as a cancer target[2]

How PNC-27 Is Dosed in Research

Because PNC-27 is still in preclinical (cell and lab) research, there are no established human dosing protocols. Published studies have used a range of concentrations on cell cultures to build dose-response curves — for example, one cervical cancer study identified an IC50 around 12.4 µM in that specific cell line.[4] For a full breakdown of the concentrations used across different studies, see the dosage chart on this page. You can also use the calculator to convert between units commonly reported in research papers. These figures are for reference only and do not constitute medical advice.

Mixing and Storing PNC-27

In research settings, lyophilized (freeze-dried) peptides like PNC-27 are typically reconstituted — meaning dissolved — using sterile water or a dilute acetic acid solution, depending on the peptide's solubility profile. The vial should be gently swirled, never shaken vigorously, to avoid breaking down the peptide structure. Reconstituted solutions are generally aliquoted into single-use portions and stored at −20 °C or colder to prevent degradation. Avoid repeated freeze-thaw cycles. Always check the manufacturer's or supplier's certificate of analysis for specific handling instructions, and work under appropriate laboratory conditions. PNC-27 is a research reagent only.

Sources

  1. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. — Biomedicines, 2022. PMID 35625682.
  2. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption. — Annals of clinical and laboratory science, 2024. PMID 38802154.
  3. Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: In vitro study. — Iranian journal of basic medical sciences, 2022. PMID 36311203.
  4. HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells. — Annals of clinical and laboratory science, 2025. PMID 40750238.
  5. Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells. — Anticancer research, 2020. PMID 32878773.
  6. Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer. — Annals of clinical and laboratory science, 2017. PMID 28667027.

PNC-27 Preguntas

What is PNC-27?
PNC-27 is a synthetic 32-amino-acid research peptide built from two parts: a segment of the tumor-suppressor protein p53 that normally binds to HDM-2, and a cell-penetrating leader sequence. Together they create a molecule that researchers are studying for its ability to selectively target cancer cells that display HDM-2 on their outer membrane, while leaving normal cells alone.[1]
How does PNC-27 work?
PNC-27 binds to HDM-2 protein displayed on the outer surface of cancer cell membranes — a feature largely absent from healthy cells. Once bound, multiple PNC-27/HDM-2 complexes cluster into ring-shaped structures that punch physical pores through the membrane, causing the cancer cell to leak its contents and die by necrosis.[1] PNC-27 may also enter cells and disrupt mitochondrial membranes.[2]
What is PNC-27 used for in research?
Lab studies have explored PNC-27's effects on leukemia cells,[5] cervical cancer cells,[4] pancreatic cancer cells,[2] and ovarian cancer cells.[6] It has also been attached to iron oxide nanoparticles to investigate its potential as a cancer-targeting agent for diagnostic imaging.[3] All use is strictly preclinical research at this stage.
How is PNC-27 dosed?
There are no established human dosing guidelines for PNC-27. In cell-culture research, concentrations vary by cancer type and study design — for instance, an IC50 of approximately 12.4 µM was reported in one cervical cancer cell line.[4] See the dosage chart on this page for a compiled reference of concentrations used in published studies. This is not medical advice.
How do you reconstitute PNC-27?
Lyophilized research peptides are typically reconstituted with sterile water or dilute acetic acid. The solution should be gently swirled — not shaken — then aliquoted and stored at −20 °C or below. Repeated freeze-thaw cycles should be avoided as they can degrade the peptide. Always follow the specific instructions provided with the research-grade material you are using.
Is PNC-27 safe?
PNC-27 has not been evaluated for safety in humans. In cell-culture studies, it has repeatedly shown selectivity for cancer cells over normal cells — for example, normal cervical cells[4] and normal blood-forming cells[5] were unharmed while cancerous counterparts were killed. However, laboratory findings do not predict human safety. PNC-27 is a research compound only and should not be used in humans.